Drugs

SILVER SPRING, Md., July 28, 2021 /PRNewswire/ — Today, the U.S. Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus. Semglee (insulin glargine-yfgn) is both biosimilar to, and interchangeable with (can be
0 Comments
The pharmaceutical giant’s Q2 revenues reached $19bn, reflecting 86% operational growth thanks to the COVID-19 vaccine which contributed $7.8bn in direct sales and alliance revenues. Excluding the COVID-19 vaccine, revenues grew 10% to $11.1bn. 2.1 billion doses now on order for 2021 Pfizer’s earlier revenue estimates of $26bn for the COVID-19 vaccine was based on
0 Comments
faricimab Treatment for Wet Age-Related Macular Degeneration (AMD); Diabetic Macular Edema (DME) FDA Accepts Application for Genentech’s Faricimab for the Treatment of Wet Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME) South San Francisco, CA — July 28, 2021 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced
0 Comments
oteseconazole Treatment for Vaginal Candidiasis Mycovia Pharmaceuticals Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis  DURHAM, N.C.–(BUSINESS WIRE) July 28, 2021 –Mycovia Pharmaceuticals, Inc. (Mycovia), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel
0 Comments
FDA Approves Twyneo (tretinoin and benzoyl peroxide) for the Treatment of Acne Vulgaris NESS ZIONA, Israel, July 27, 2021 (GLOBE NEWSWIRE) — Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Food and Drug
0 Comments
The all-stock asset acquisition is valued at $58.7m.  AC Immune – a Swiss biopharmaceutical company working on precision medicine for neurodegenerative diseases – says the acquisition will make it ‘a leader in the development of therapeutics and diagnostics for Parkinson’s disease’. It will immediately launch a Phase 2 study for the newly acquired vaccine candidate.
0 Comments
As a global provider of life science antibodies and reagents, privately-held BioLegend has more than 700 employees (primarily in the US) with estimated 2022 revenues of $380m and a manufacturing facility in San Diego, California. Itprovides academic and biopharmaceutical customers with antibodies and reagents in high-growth areas such as cytometry, proteogenomics, multiplex assays, recombinant proteins,
0 Comments
KENILWORTH, N.J.–(BUSINESS WIRE) July 27, 2021 — Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment and
0 Comments
sulopenem Treatment for Bacterial Infection Iterum Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Oral Sulopenem DUBLIN, Ireland and CHICAGO, July 26, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by
0 Comments
News New Drug Applications FDA Accepts Braeburn’s New Drug Application Resubmission for Brixadi (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder Treatment for Opiate Dependence FDA Accepts Braeburn’s New Drug Application Resubmission for Brixadi (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder Plymouth Meeting, Pa. – June 26, 2021
0 Comments
The $39bn deal, announced in December 2020, is AstraZeneca’s largest ever acquisition: allowing it to move further into immunology with an enhanced scientific presence, and giving it Alexion’s lead medicine soliris (eculizumab), among four other approved medicines and a pipeline of 11 molecules. AstraZeneca predicts Alexion will deliver double-digit average annual revenue growth through 2025:
0 Comments
The COVID-19 pandemic saw greater flexibility in the regulatory approach to prevent drug shortages. Some commentators have asked whether the agency’s new experience with and comfort from exercise of its emergency use authorization (EUA) authority during the coronavirus crisis was a factor in the recent accelerated approval of Biogen’s Alzheimer’s drug, a move that attracted
0 Comments
WILMINGTON, Del.–(BUSINESS WIRE) July 23, 2021–AstraZeneca’s Bydureon BCise (exenatide extended-release), once-weekly injectable suspension has been approved in the US for the treatment of type 2 diabetes (T2D); to improve glycemic control in pediatric patients (10 to 17 years) as an adjunct to diet and exercise. The approval by the US Food and Drug Administration (FDA)
0 Comments
NORTH CHICAGO, Ill., July 23, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved Dalvance® (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth. Dalvance is the first single-dose option administered as a 30-minute intravenous (IV) infusion for
0 Comments
July 19, 2021 Audience: Consumer Tucson, AZ, Alpha Male Plus is voluntarily recalling all lots within expiry of Alpha Male Plus Male Enhancer fruit chews to the consumer level. FDA analysis has found the product to be tainted with tadalafil, an ingredient known as a phosphodiesterase (PDE-5) inhibitor found in a FDA approved product for
0 Comments
The plant, equipped with 2D/3D bioreactors, will enhance its existing stem cell research and repository capabilities with mesenchymal stem cell (MSC) biologics manufacturing, said the company. Generate said the site will allow it to add the role of therapeutics developer with in-house manufacturing capabilities to its core international donor gamete, genetics service and newborn stem
0 Comments
Thanks to Biovac’s manufacturing facilities in Cape Town, the deal will add a third continent to the mRNA vaccine’s supply chain and manufacturing network (with production to date having taken place in North America and Europe). Technical transfer, on-site development and equipment installation will begin at the site immediately. This will allow the facility to
0 Comments